From Financial Modeling Prep: 2025-02-20 09:00:05

In anticipation of TransMedics Group, Inc.’s quarterly earnings report, analysts predict an EPS of $0.22 and revenue of around $109.5 million. The company’s Organ Care System (OCS) positions them as a key player in the medical technology sector, competing with others in organ preservation solutions.

Legal troubles loom as a class action lawsuit has been filed against TransMedics, potentially impacting investor sentiment and stock performance. The deadline for affected investors to join the lawsuit is April 15, 2025. Recovery options under federal securities laws are available for those who have suffered losses.

TransMedics’ financial health indicators include a high P/E ratio of 81.37, reflecting strong investor confidence in future growth. However, the high ratio may suggest an overvalued stock. With a debt-to-equity ratio of 2.47, the company relies on debt financing, while a current ratio of 8.20 indicates a strong ability to cover short-term liabilities.



Read more at Financial Modeling Prep:: TransMedics Group, Inc. (NASDAQ:TMDX) Quarterly Ea…